Skip to main content

23-09-2020 | Oncology | News | Article

ESMO 2020

IMvigor130 PROs add support for atezolizumab–chemotherapy use in advanced UC

Shreeya Nanda

medwireNews: The addition of atezolizumab to standard first-line chemotherapy does not adversely affect the quality of life (QoL) of patients with locally advanced or metastatic urothelial carcinoma (UC), report the IMvigor130 investigators.

Presenting author Aristotelis Bamias (National & Kapodistrian University of Athens, Greece) said that these patient-reported outcomes (PROs), together with the previously reported progression-free survival benefit and satisfactory safety profile, support the combination of atezolizumab and chemotherapy “as an important new treatment option for patients with untreated metastatic urothelial cancer.”

As reported at the ESMO Virtual Congress 2020, baseline PRO data, assessed using the EORTC QLQ-30 scale, were available for 363 participants who were randomly assigned to receive atezolizumab 1200 mg every 3 weeks alongside gemcitabine plus cisplatin or carboplatin and 327 patients who instead received placebo plus chemotherapy.

Time to deterioration, defined as the time to a change from baseline of at least 10 points, favored the atezolizumab group for global health status (median 24.8 vs 16.6 months) as well as for most of the function and symptom subscales. The only exceptions were the dyspnea symptom and physical function subscales, which favored the placebo group.

Analyses of changes from baseline did not show any clinically meaningful worsening for either global health status or any of the function and symptom subscales with the addition of atezolizumab to chemotherapy. And indeed, there was a trend toward a clinically relevant improvement for overall QoL and some subscales, such as role and emotional function.

The presenter cautioned, however, that these PRO analyses were exploratory and analyzed using descriptive statistics.

Bamias summarized that “patients in both arms reported similar changes, either maintaining or even improving over pretreatment levels, in most symptom, function, or quality of life domains, which suggests a positive overall impact of therapy on the patients.”

And he concluded: “This analysis shows that the addition of atezolizumab to chemotherapy results in prolongation of progression-free survival without compromising patients’ function or quality of life.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

ESMO Virtual Congress 2020: 19–21 September

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage